All material on this website is aimed at healthcare professionals working in BaNES, Swindon and Wiltshire.
Members of the public seeking advice on medicine-related matters are encouraged to speak with their GP, pharmacist or nurse, or out of hours contact the NHS 111 service by telephoning 111.
SCAs outline ways in which the responsibilities for managing the prescribing of a medicine can be shared between the specialist and a primary care prescriber. Primary care prescribers are invited to participate. If they are unable to undertake these roles, then they are under no obligation to do so. In such an event, the total clinical responsibility for the patient for that diagnosed condition remains with the specialist.
AMBER with SHARED CARE medicines require significant monitoring and to qualify must be designated so by the BSW APC. Primary care prescribers are advised not to take on prescribing of these medicines unless they have been adequately informed in writing (by letter or via secure email) of their responsibilities with regards to monitoring, side effects and interactions and are happy to take on the prescribing responsibility. A copy of the locally approved SCA should accompany the request. Primary care prescribers should reply to the request as soon as practicable if they are unable to support shared care (in writing or via secure email) and then arrange the transfer of care as necessary. This will ensure absolute clarity as to who is taking over the prescribing and any associated monitoring responsibilities.
Sharing of care assumes communication between the specialist, primary care prescriber and patient. The intention to share care is usually explained to the patient by the prescriber initiating treatment. It is important that patients are consulted about treatment and are in agreement. Where appropriate, patients should remain under regular follow-up in secondary care, where it is expected that the patient’s overall response to treatment and need for continued treatment will be monitored.
The APC are working to review and align Traffic Light Statuses (TLS) and SCAs across BSW. Where differences in TLS and SCAs exist, clinicians should refer to the agreement for their locality.
A full list of SCAs agreed for BSW are listed below (A-Z) and are also available in the relevant drug entry or section on the formulary website bswformulary.nhs.uk
The formulary and APC websites remain under development. For further information or to report inaccuracies/feedback email email@example.com
Alfacalcidol for Hypocalcaemia due to Hypoparathyroidism in Adults (RUH)
Apixaban, Edoxaban or Rivaroxaban for the OFF-LABEL Treatment of Cancer Associated Thrombosis (RUH and SFT)
ApixabanDOAC edoxaban rivaroxaban thrombosis DVT VTECAT
Atomoxetine, Dexamfetamine, Lisdexamfetamine and Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
MethylphenidateAtomoxetineLisdexamfetaminedexamfetamineAttention Deficit Hyperactivity Disorder
Atomoxetine, Dexamfetamine, Lisdexamfetamine, Methylphenidate and Guanfacine for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents
Methylphenidate atomoxetine lisdexamfetamine Dexamfetamine ADHDguanfacine intuniv
Azathioprine and Mercaptopurine for Ulcerative Colitis, Crohn’s Disease and Autoimmune Hepatitis (GWH)
Ulcerative colitisCrohn’s diseaseAutoimmune hepatitis
BSW Buccolam® (Oromucosal Buccal Midazolam) as an Intervention for Prolonged Seizures and Prevention of Status Epileptics in Children
BSW Epistatus® (Oromucosal Buccal Midazolam) as an intervention for prolonged seizures and prevention of status epileptics in children
epilepsyfittingfitsepileptic fitseizurebuccolamstatus epilepticus
BSW Sildenafil for digital ulceration and severe Raynaud’s (unlicensed indication)
sildenafilraynaudsconnective tissue disorderdigital ulcer
Dalteparin for the treatment of cancer associated thrombosis (RUH and SFT)
Dalteparin LMWH thrombosis DVT VTE
Denosumab Shared Care Guideline for Osteoporosis